AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi

Pharma borg AbbVie hasn’t had many roadblocks on its path to dominance with megablockbuster Humira regularly topping pharma’s bestseller list. But Humira’s days on top are numbered, and AbbVie is making the case for newer immunology meds like IL-23 Skyrizi to help take the sting out of a costly 2023 patent cliff.